Stanford researchers have developed a general system to regulate the activities of specific proteins in mammalian cells using cell-permeable, synthetic molecules.
Stanford researchers have patented a system for precise genetic modification of human embryonic stem cells (ECSs) and induced pluripotent stem cells (iPSCs).
Researchers at Stanford have created ligand-induced dimerization activating RNA editing (LIDAR), a versatile molecular sensor that turns the presence of a ligand into translation of an output protein.
Researchers in Prof. Karl Diesseroth's laboratory have discovered a Dopamine receptor type 2 specific promoter (D2SP) that can be used to transfect, identify and isolate Dopamine R2 (D2R)-expressing cells.
RNA replication and amplification have broad applications across biomedicine, but current methods are limited by a reliance on inefficient, multi-step protocols.
Stanford researchers have developed a new class of materials that enable new strategies for the efficient delivery of messenger RNA (mRNA) into cells and animals. The delivery materials are easily prepared (2 steps), stable and readily tuned.
A team of Stanford scientists have developed a technique to rapidly convert adult somatic cells directly into functional neuronal cells without the intermediate step of generating iPS cells (induced pluripotent stem cells).
Dr. Mark Kay and colleagues have created antibiotic-selectable, non-silencing plasmid vectors that can be prepared by conventional methods and provide persistent high levels of transgene expression.
Stanford researchers have patented protein stability regulation methods using destabilizing domains (DDs) optimized for use in humans. The ability to control specific protein abundance in cells is a powerful tool for gene therapy and investigating biological behavior.
Enzymatically active hydrogenase is synthesized in a cell-free reaction. The hydrogenases are synthesized in a cell-free reaction comprising a cell extract derived from microbial strains expressing at least one hydrogenase accessory protein.
Researchers in Dr. Mark Kay's laboratory at Stanford University have designed a new liver-specific expression cassette for inserting genes into double-stranded AAV (adeno-associated virus) vectors for gene therapy.